Moberg Pharma Past Earnings Performance

Past criteria checks 0/6

Moberg Pharma's earnings have been declining at an average annual rate of -58.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 70.9% per year.

Key information

-58.3%

Earnings growth rate

-62.3%

EPS growth rate

Pharmaceuticals Industry Growth30.5%
Revenue growth rate-70.9%
Return on equity-2.0%
Net Margin-207.8%
Next Earnings Update11 Feb 2025

Recent past performance updates

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Revenue & Expenses Breakdown

How Moberg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:MOB Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249-18302
30 Jun 245-23303
31 Mar 241-23274
31 Dec 230-21254
30 Sep 230-18233
30 Jun 230-16222
31 Mar 230-16221
31 Dec 220-16211
30 Sep 220-17202
30 Jun 220-16192
31 Mar 220-16183
31 Dec 210-16193
30 Sep 21348215
30 Jun 21347216
31 Mar 21345226
31 Dec 20347226
30 Jun 205020247
30 Jun 1931-83113
31 Mar 194553126918
31 Dec 185-282613
30 Sep 18341921716
30 Jun 183401921015
31 Mar 18334620614
31 Dec 174391126114
30 Sep 17438-126815
30 Jun 17434025315
31 Mar 173693521813
31 Dec 163343320112
30 Sep 162993618115
30 Jun 162613216815
31 Mar 16282916519
31 Dec 152862615923
30 Sep 152762515822
30 Jun 152602015025
31 Mar 152261913023
31 Dec 142001212020
30 Sep 141931211220
30 Jun 14179411021
31 Mar 14167-511125
31 Dec 13157-1110429

Quality Earnings: MOB is currently unprofitable.

Growing Profit Margin: MOB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MOB is unprofitable, and losses have increased over the past 5 years at a rate of 58.3% per year.

Accelerating Growth: Unable to compare MOB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: MOB has a negative Return on Equity (-1.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Moberg Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bjorn RydellABG Sundal Collier Sponsored
Klas PykNordea Markets
Mats HyttingeRedeye